drugset / Trial / NCT05338580
Clinical Trial of TJ271 Injection Combined With Pembrolizumab in the Treatment of Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
A Multi-center, Open-label Phase II Clinical Trial of TJ271 Injection in Combination with Pembrolizumab in Chinese Patients with Advanced Solid Tumors to evaluate the anti-tumor efficacy, safety, pharmacokinetics and immunogenicity of TJ271 in combination with pembrolizumab in patients with advanced solid tumors.
Timeline
- Start
- 2023-12-31
- Primary completion
- 2023-12-31
- Completion
- 2023-12-31
Outcome
Outcome not reported
Stopped (Business): “Company Development strategy adjustment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | — | — |
| Subject | TJ271 | Unknown | — | — |